{"id":293322,"date":"2024-06-18T00:00:00","date_gmt":"2024-06-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2024-biopharma-psoriasis-access-reimbursement-access-reimbursement-psoriasis-us\/"},"modified":"2026-03-31T10:29:29","modified_gmt":"2026-03-31T10:29:29","slug":"acreim0017-2024-biopharma-psoriasis-access-reimbursement-access-reimbursement-psoriasis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2024-biopharma-psoriasis-access-reimbursement-access-reimbursement-psoriasis-us\/","title":{"rendered":"Psoriasis – Access & Reimbursement – Access & Reimbursement \u2013 Psoriasis (US)"},"content":{"rendered":"
\n
\n

The arrival of newer and more effective treatments in the U.S. psoriasis market is changing the treatment landscape and fueling competition for favorable coverage from MCO<\/abbr>s. After years of dominance of well-entrenched biologics, such as AbbVie\u2019s Humira, Janssen\u2019s Stelara, and Novartis\u2019s Cosentyx, newer agents like Amgen\u2019s oral PDE<\/abbr>-4 inhibitor Otezla, Eli Lilly\u2019s IL<\/abbr>-17 inhibitor Taltz, and Janssen\u2019s IL<\/abbr>-23 inhibitor Tremfya have successfully found their place in the treatment algorithm. AbbVie\u2019s Skyrizi, the latest IL<\/abbr>-23 inhibitor, outperforms earlier biologics on the market and is gaining on the established market leaders. The recent entries of Sotyktu (BMS<\/abbr>\u2019s oral TYK2<\/abbr> inhibitor) and Bimzelx (UCB\u2019s IL<\/abbr>-17 A\/F dual inhibitor), along with the increasing penetration of adalimumab biosimilars, are further intensifying the competition. This report provides valuable insights into how payer coverage policies influence dermatologists\u2019 prescribing decisions, helping marketers navigate this challenging market access environment.<\/p>\n<\/div>\n

\n

QUESTIONS ANSWERED<\/strong><\/p>\n<\/div>\n

    \n
  • Among commercially insured psoriasis patients, what percentage receive newer targeted agents, and how do MCO<\/abbr> restrictions impact physicians\u2019 prescribing of biologics \/ oral targeted agents?<\/li>\n
  • How do payers cover biosimilar versions of adalimumab (e.g., Amgen\u2019s Amjevita, Boehringer Ingelheim\u2019s Cyltezo), and how do physicians prescribe these biosimilars?<\/li>\n
  • How do MCO<\/abbr>s cover branded biologics \/ oral targeted agents in their largest fully insured commercial plans, and what economic factors most influence favorable coverage?<\/li>\n<\/ul>\n
    \n

    PRODUCT DESCRIPTION<\/strong><\/p>\n<\/div>\n

    \n

    U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n<\/div>\n

    \n

    SOLUTION ENHANCEMENT<\/b><\/p>\n<\/div>\n

    \n

    Access & Reimbursement includes key analyses from Clarivate Real-World Data Product\u2014comprehensive and timely data that provide clarity around the healthcare experiences and activities of hundreds of millions of patients, HCP<\/abbr>s, and payers. Analyses include payer mix, percentage of claim rejections for key therapies, and reasons for claim rejection.<\/p>\n<\/div>\n<\/div>\n

    Key drugs<\/strong>: Humira, Amjevita, Enbrel, Remicade, Inflectra, Renflexis, Avsola, Cimzia, Stelara, Otezla, Cosentyx, Taltz, Siliq, Tremfya, Ilumya, Skyrizi, Bimzelx, Sotyktu<\/p>\n

    Key companies: <\/strong>AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB<\/span><\/p>\n","protected":false},"template":"","class_list":["post-293322","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293322\/revisions"}],"predecessor-version":[{"id":575946,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293322\/revisions\/575946"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}